RxDoctor Payments Data

Ruthann Allison

Psychiatric/Mental Health · Florence, ALNPI 1013466911

Payments from drug & device makers

$979in general payments, 2019–2025

Across 38 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$293
  • Johnson & Johnson$193
  • Avanir Pharmaceuticals, Inc.$127
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • Neurocrine Biosciences, Inc.$55
  • Otsuka America Pharmaceutical, Inc.$50
  • plus $201 from 7 others

What the payments were for

  • Food & beverage$979100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$979 in reported general payments places this provider in the 50th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$180,664
Medicare patients
323
Services billed
2,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole11$30,463
NuedextaDextromethorphan Hbr/Quinidine35$16,216
Divalproex Sodium287$11,157
Duloxetine Hcl200$6,758
Mirtazapine256$5,155
Sertraline Hcl325$4,567
Trazodone Hcl305$3,843
Quetiapine Fumarate240$3,640
Ziprasidone Mesylate17$3,449
Fluoxetine Hcl173$3,310
Memantine Hcl115$3,293
Paliperidone ErPaliperidone14$3,260
Olanzapine121$3,229
Aripiprazole70$2,817
Buspirone Hcl145$2,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$50$30,46311 claims
Avanir Pharmaceuticals, Inc.Nuedexta$127$16,21635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →